全文获取类型
收费全文 | 325875篇 |
免费 | 20338篇 |
国内免费 | 1392篇 |
专业分类
耳鼻咽喉 | 3552篇 |
儿科学 | 8301篇 |
妇产科学 | 5982篇 |
基础医学 | 40581篇 |
口腔科学 | 5976篇 |
临床医学 | 33684篇 |
内科学 | 67533篇 |
皮肤病学 | 4465篇 |
神经病学 | 32830篇 |
特种医学 | 13568篇 |
外国民族医学 | 16篇 |
外科学 | 51581篇 |
综合类 | 3532篇 |
现状与发展 | 1篇 |
一般理论 | 304篇 |
预防医学 | 24234篇 |
眼科学 | 7459篇 |
药学 | 21325篇 |
1篇 | |
中国医学 | 415篇 |
肿瘤学 | 22265篇 |
出版年
2023年 | 1840篇 |
2022年 | 3040篇 |
2021年 | 7174篇 |
2020年 | 4231篇 |
2019年 | 6909篇 |
2018年 | 8321篇 |
2017年 | 6088篇 |
2016年 | 6635篇 |
2015年 | 7744篇 |
2014年 | 11459篇 |
2013年 | 15488篇 |
2012年 | 23991篇 |
2011年 | 25186篇 |
2010年 | 14199篇 |
2009年 | 13047篇 |
2008年 | 22291篇 |
2007年 | 23352篇 |
2006年 | 22675篇 |
2005年 | 22242篇 |
2004年 | 21095篇 |
2003年 | 19189篇 |
2002年 | 18368篇 |
2001年 | 2700篇 |
2000年 | 1943篇 |
1999年 | 2832篇 |
1998年 | 3884篇 |
1997年 | 3064篇 |
1996年 | 2614篇 |
1995年 | 2389篇 |
1994年 | 2069篇 |
1993年 | 2013篇 |
1992年 | 1392篇 |
1991年 | 1300篇 |
1990年 | 1088篇 |
1989年 | 1015篇 |
1988年 | 941篇 |
1987年 | 874篇 |
1986年 | 864篇 |
1985年 | 946篇 |
1984年 | 1181篇 |
1983年 | 1016篇 |
1982年 | 1350篇 |
1981年 | 1233篇 |
1980年 | 1044篇 |
1979年 | 549篇 |
1978年 | 633篇 |
1977年 | 550篇 |
1976年 | 494篇 |
1975年 | 376篇 |
1974年 | 368篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
OBJECTIVE: The authors examined whether physicians' use of computerized decision aids affects patient satisfaction and/or blame for medical outcomes. METHOD: Experiment 1: Fifty-nine undergraduates read about a doctor who made either a correct or incorrect diagnosis and either used a decision aid or did not. All rated the quality of the doctor's decision and the likelihood of recommending the doctor. Those receiving a negative outcome also rated negligence and likelihood of suing. Experiment 2: One hundred sixty-six medical students and 154 undergraduates read negative-outcome scenarios in which a doctor either agreed with the aid, heeded the aid against his own opinion, defied the aid in favor of his own opinion, or did not use a decision aid. Subjects rated doctor fault and competence and the appropriateness of using decision aids in medicine. Medical students made judgments for themselves and for a layperson. RESULTS: Experiment 1: Using a decision aid caused a positive outcome to be rated less positively and a negative outcome to be rated less negatively. Experiment 2: Agreeing with or heeding the aid was associated with reduced fault, whereas defying the aid was associated with roughly the same fault as not using one at all. Medical students were less harsh than undergraduates but accurately predicted undergraduate's responses. CONCLUSION: Agreeing with or heeding a decision aid, but not defying it, may reduce liability after an error. However, using an aid may reduce favorability after a positive outcome. 相似文献
62.
Ronald Martin Jaime Williams Thomas Hadjistavropoulos Heather D Hadjistavropoulos Michael MacLean 《Revue canadienne de recherche en sciences infirmières》2005,37(2):142-164
The literature suggests that pain in the elderly, especially among seniors with dementia, is under-assessed and under-treated.This qualitative study solicited the perspectives of seniors, front-line nursing staff, nursing-home administrators, and informal caregivers of seniors with dementia on the current status of pain assessment and management. The views of these participants complement the research findings reported in the literature. While some of their explanations and potential solutions concerning under-treatment of pain in seniors echo views that have been presented in the literature, the participants also pointed to factors and avenues that have been given less formal consideration (e.g., systemic barriers to effective assessment and treatment of pain).They also highlighted the need for pain-control strategies beyond medication. The implications of these findings are discussed. 相似文献
63.
Susan B Fowler Michael Moussouttas Barbara Mancini 《The Journal of neuroscience nursing》2005,37(4):220-223
Metabolic syndrome is associated with increased risk for cardiovascular and cerebrovascular disease. The World Health Organization and National Cholesterol Education Program Adult Treatment Panel III have identified physiologic abnormalities associated with metabolic syndrome, including impaired glucose metabolism, high blood pressure, elevated cholesterol levels, and abdominal obesity. It is estimated that 47 million Americans have metabolic syndrome. A variety of therapies may help reduce the incidence and risk, including diet, weight loss, physical exercise, glycemic control, and pharmacological treatments. Nursing care is focused on developing an individualized plan of care that includes family members and providing education, psychosocial support, close monitoring, and continued follow-up to ensure adherence and success in achieving patient outcomes. 相似文献
64.
65.
66.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
67.
68.
69.
Michael R Horsman 《International journal of hyperthermia》2006,22(3):197-203
The most important physiological parameter influencing tissue response to heat is blood flow. At mild hyperthermia temperatures blood perfusion increases in many tumours and this effect is heating time-, temperature- and tumour-dependent. These flow increases can improve tumour oxygenation. When heating is terminated, perfusion and oxygenation commonly recover, although how quickly this occurs appears to be tumour-specific. While these effects are unlikely to have any anti-tumour activity they can be exploited to improve the combination of heat with other therapies. However, since similar physiological effects should occur in normal tissues, such combination therapies must be carefully applied. Heating tumours to higher temperatures typically causes a transient increase in perfusion during heating, followed by vascular collapse which if sufficient will increase tumour necrosis. The speed and degree of vascular collapse is dependent on heating time, temperature and tumour model used. Such vascular collapse generally occurs at temperatures that cause a substantial blood flow increase in certain normal tissues, thus preferential anti-tumour effects can be achieved. The tumour vascular supply can also be exploited to improve the response to heat. Decreasing blood flow, using transient physiological modifiers or longer acting vascular disrupting agents prior to the initiation of heating, can both increase the accumulation of physical heat in the tumour, as well as increase heat sensitivity by changing the tumour micro-environmental parameters, primarily an increase in tumour acidity. Such changes are generally not seen in normal tissues, thus resulting in a therapeutic benefit. 相似文献
70.
Xenotransplantation is being developed in the hope of resolvingthe critical shortage of donor organs for transplantation. TheEurotransplant waiting lists [1] for donor organs of variouskinds number almost 16 000 patients and the US lists [2] morethan 90 000 patients. Renal transplantation, for instance, cost-effectivelyconfers a significant survival advantage [3] and improvementof quality of life [4]. But whereas currently, in Europe, nearly12 000 end-stage renal disease patients await a suitable donor,only 3383 kidney transplants were performed in 2005, with anaverage waiting time of 1174 days [1]. Substantial researchefforts are being made in the field of xenotransplantation,and the immunological barriers are gradually being elucidated.Pig-to-human xenogeneic 相似文献